Available to Media Immediately Following in Room 217C
Newswise — Dennis Slamon, M.D., Ph.D., director of clinical/translational research for the Revlon/University of California, Los Angeles (UCLA) Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center, will present updated results of his groundbreaking work with trastuzumab, currently sold as Herceptin by Genentech-Roche.
Slamon will present his study at the CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12, 2009, at 9:45 a.m. CT, in the main lecture hall.
Immediately following this presentation, he will take questions from registered media representatives in room 217C of the Henry B. Gonzales Convention Center, San Antonio.
Reporters who cannot attend in person can participate by using the following information:
• U.S. & Canada: (888) 282-7404• International: (706) 679-5207• Access Code: 44493090• Topic: AACR
Herceptin changed the face of breast cancer treatment when it was approved in 1998 for the treatment of HER2-positive breast cancer. These updated results will focus on disease-free survival, overall survival and cardiac toxicity, according to Slamon.
“The results of this trial help define the role of Herceptin in the breast cancer HER2-positive adjuvant setting, as well as the risks and benefits of adjuvant therapy within the context of overall safety including cardiac toxicity,” said Slamon.
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR’s scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 32nd annual symposium is expected to draw more than 8,500 participants from more than 90 countries.
RSS